Cell therapy · developed by Longeveron
allo-hMSCs are allogeneic human mesenchymal stem cells, cell-based agents studied in frailty and hypoplastic left heart syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02065245 | Phase 1/2 | Frailty | Completed | LGVN |
| NCT02398604 | Phase 1 | Hypoplastic Left Heart Syndrome | Terminated | LGVN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
FrailtyHypoplastic Left Heart Syndrome
Updated Oct 18, 2026. Something wrong or missing? Report it on the LGVN page.
See LGVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LGVN catalysts and pipeline →